BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9457397)

  • 1. Renal cell carcinoma and interleukin-2: what are the endpoints?
    Figlin RA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S68-9. PubMed ID: 9457397
    [No Abstract]   [Full Text] [Related]  

  • 2. Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.
    NĂ©grier S
    J Clin Oncol; 2004 Apr; 22(7):1174-6. PubMed ID: 14981101
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 5. [The immunotherapy of advanced renal cell carcinoma].
    Bergmann L; Weidmann E; Mitrou PS
    Dtsch Med Wochenschr; 1991 Mar; 116(10):384-90. PubMed ID: 1705879
    [No Abstract]   [Full Text] [Related]  

  • 6. Relapse after successful treatment with immunotherapy: lessons for the future.
    Fisher RI
    Cancer J Sci Am; 1998; 4(2):78-9. PubMed ID: 9532407
    [No Abstract]   [Full Text] [Related]  

  • 7. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.
    Correale P; Marsili S; Sabatino M; Montagnani F; Giorgi G; Francini G
    Oncol Rep; 2005 Apr; 13(4):751-6. PubMed ID: 15756453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic renal cell carcinoma: systemic treatment.
    Abi-Aad AS; deKernion JB
    Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
    [No Abstract]   [Full Text] [Related]  

  • 10. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic approaches for renal cancer.
    Pizza G; de Vinci C; Viza D
    Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-2.
    Med Lett Drugs Ther; 1987 Sep; 29(749):88-9. PubMed ID: 3306301
    [No Abstract]   [Full Text] [Related]  

  • 13. [Carcinogenesis and immunobiology of tumors. Scientific and clinical aspects].
    Granov AM; Molchanov OE
    Vopr Onkol; 2008; 54(4):401-9. PubMed ID: 18942393
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of renal cell carcinoma with mediastinal lymph node metastasis by interleukin-2: a case report.
    Tokunaga M; Masuda A; Mukai M; Nakamura H; Iwaki K; Terachi T
    Tokai J Exp Clin Med; 2005 Jul; 30(2):111-5. PubMed ID: 16146201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
    Leppert JT; Lam JS; Belldegrun AS
    J Immunother; 2005; 28(5):427-9. PubMed ID: 16113598
    [No Abstract]   [Full Text] [Related]  

  • 18. Sarcomatoid renal cell carcinoma.
    Akhtar K; Shamshad A; Sufian Z; Tariq M
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):120-2. PubMed ID: 21196626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic therapy of metastatic renal cell carcinoma.
    Vugrin D
    Semin Nephrol; 1987 Jun; 7(2):152-62. PubMed ID: 2442806
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.